Implantica (IMP) Q3 2024 earnings summary

Executive summary

• Q3 2024 net sales reached EUR 344,000, up 41% year-over-year, driven by RefluxStop/RefluxStop™ sales and strong clinical outcomes among European key opinion leaders.

• Operating loss (EBIT) narrowed 7% to EUR 5.3 million in Q3, while net loss increased to EUR 6.4 million due to higher financial expenses.

• Cash and cash equivalents at end of September totaled EUR 69.3 million, with no interest-bearing debt and a 96.2% equity ratio.

• Over 1,000 RefluxStop surgeries performed in Europe, with growing surgeon interest and strong clinical results.

• U.S. and Japan market entry preparations underway, with significant interest from leading centers and surgeons.

Financial highlights

• Adjusted gross margin for Q3 was 97%, up from 94% in Q3 2023; nine-month margin at 93%.

• Q3 operating loss was EUR 5.3 million, a 7% decrease year-over-year; net loss increased to EUR 6.4 million.

• R&D expenses in Q3 rose 17% to EUR 2.5 million, mainly from FDA-related costs.

• Cash and cash equivalents at EUR 69.3 million; no interest-bearing debt.

• Quarterly operating cash outflow was EUR 4.8 million.

Outlook and guidance

• Focus on expanding reimbursement and market access in Europe and internationally to accelerate sales.

• U.S. FDA PMA process ongoing, with module three submission expected in approximately three months; Japanese approval process initiated.

• Anticipates substantial US commercial footprint within 1–2 years post-FDA approval, leveraging strong clinical data.

• Randomized controlled trial comparing RefluxStop to Nissen fundoplication enrolling 200 patients, with first results expected within 1–1.5 years after enrollment.